Multiple Myeloma
As transplantation-related complications are high among patients with MDS, determining which patients will benefit from HSCT is essential.
Hematologic Cancers
Premyelodysplastic syndrome blood kinetics are linked to both disease risk and overall survival.
Hematologic Cancers
The administration of cedazuridine with decitabine prevents the degradation of decitabine by CDA in the gastrointestinal tract and liver increasing its systemic exposure.
Hematologic Cancers
Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.
Hematologic Cancers
Given the prevalence, the IWG-PM evaluated available evidence to determine whether SF3B1-mutated MDS should be recognized as a distinct disease subtype.
Hematologic Cancers
The FDA has approved Reblozyl® (luspatercept–aamt; Bristol-Myers Squibb and Acceleron) for the treatment of anemia in adults with lower-risk myelodysplastic syndromes.
Leukemia
With adequate support from a multidisciplinary care team, outpatient induction chemotherapy was safe for these patients.
Hematologic Cancers
Transfusion burden reduced in patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Leukemia
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
Leukemia
Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.
